Fair-Value Report — United Laboratories International Holdings (3933.HK)

Insider Signal

Verified Snapshot

Price as of 14 July 2026 per Investing.com. Financials FY2025 (year ended 31 Dec 2025) per company results announcement dated 24 March 2026. Financials reported in RMB; converted to HKD at 1 CNY = 1.085 HKD (approximate mid-rate, stated for transparency — actual rate may differ).

Business Overview

The United Laboratories International Holdings ("TUL") is one of China's leading vertically integrated pharmaceutical companies, with a presence across four business segments:

• Finished products — branded generics sold through hospital and retail channels (largest segment)
• Bulk medicine (APIs) — manufacture of active pharmaceutical ingredients, notably insulin APIs and penicillin derivatives; a significant global exporter
• Biopharmaceuticals — insulin formulations; GLP-1 products (liraglutide approved; semaglutide in production-application stage)
• Animal healthcare — growing segment, 70%+ pet products

The Group operates eleven production bases and is a Hang Seng Composite Index constituent with MSCI ESG rating A. FY2025 revenue was RMB 13,210.6M; the Group invested RMB 1,005.0M in R&D (7.6% of revenue). The key inflection story is the pivot from a pure generics platform to a biopharmaceutical/innovation company.

Pipeline Highlights

• UBT251 (GLP-1R/GIPR/GCGR triple agonist): Licensed ex-China rights to Novo Nordisk A/S; upfront payment received; potential milestone payments of up to US$1.8B. Phase II in China ongoing across obesity, diabetes, MASH, chronic kidney disease.
• UBT37034 (GLP-1/obesity): Phase I trials approved in both China and the US (FDA IND cleared).
• Liraglutide Injection: Approved for marketing in China (FY2025). Entering the commercial ramp.
• Semaglutide: Production-application stage (China); approval and launch expected imminently.
• 42 new human-use drugs under development, 23 are Class 1 new drugs — focused on endocrinology, metabolism, autoimmunity, ophthalmology, and anti-infection.
• Insulin export to Brazil set a record for Chinese products in FY2025; Belt-and-Road market expansion ongoing.

Valuation

Method: Multi-Scenario DCF + Exit P/E (Profitable Operating Pharma)

TUL is a profitable, cash-generative operating company — a DCF/exit-multiple approach is appropriate. Key inputs:

• Base year (FY2026E): Net profit ~RMB 1,707M (consensus EPS RMB 0.865 × 1,973M shares). Note: FY2025 profit was elevated partly by the Novo Nordisk UBT251 upfront; FY2026 consensus is depressed accordingly.
• WACC: 11% (risk-free 4%, equity risk premium 7%, beta ~1.0 for HK-listed Chinese pharma)
• Valuation horizon: 2 years to FY2028E, then apply exit P/E
• FX: 1 CNY = 1.085 HKD (held constant across scenarios for simplicity)
• UBT251 milestones are excluded from base and bear; partially included in bull (US$300M probability-weighted NPV)

Fair value does not include dividend income during the holding period (~HKD 0.45/share/year × 2 years ≈ HKD 0.90 additional return). Adding dividends: bear ~HKD 7.4; base ~HKD 12.9; bull ~HKD 24.9; blended ~HKD 13.4.

P/B Cross-Check

Reverse Read

At the current price of HKD 9.08, the market is implying a ~7.5× trailing P/E and 0.94× P/B — pricing in zero earnings growth, zero pipeline value (including the Novo Nordisk UBT251 deal), and ignoring the HKD 3.37/share net cash pile. The stock's EV/EBITDA of 3.2× is crisis-level for a cash-generative pharma company with a high-quality partner (Novo Nordisk) validating its pipeline. The implied price is pricing in outright business deterioration.

Peer Comparison

Peers: HK-listed China-domiciled pharmaceutical manufacturers. Data sourced from Investing.com, CNBC, and company announcements (July 2026). P/E figures are TTM or FY25A where stated.

United Laboratories trades at approximately half the P/E of its nearest generics/innovation peer CSPC, despite similar net margins and a richer pipeline-in-licensing story (Novo Nordisk). Partial peer data reflects limitations in available disclosed metrics at time of writing; interpret the table directionally.

Conclusion

Signal verdict: GENUINE and SIGNIFICANT. The HKEX Form 3A (filing ID DA20260710E00719) confirms a reason-1101 on-exchange purchase by Executive Chairman TSOI HOI SHAN on 8 July 2026 — not a placing, subscription, scheme, or intra-group reshuffle. The Chairman nearly tripled his personal stake (0.86% → 2.11%), committing an estimated HKD 222–230M of personal capital at or near the 52-week low. This is one of the largest director purchases in the company's history in absolute terms.

Fundamental verdict: CHEAP, CASH-RICH, PIPELINE-OPTIONED. At HKD 9.08, United Laboratories trades at:

• 7.5× trailing P/E vs Chinese pharma peer average of ~14×
• 3.2× EV/EBITDA (crisis-level for a debt-free, cash-generative company)
• 0.94× book with net cash of HKD 3.37/share (37% of market cap)
• A 5.0% dividend yield (38% payout ratio, well-covered)
• Zero assigned value to UBT251 (licensed to Novo Nordisk; up to US$1.8B in milestones)
• Zero assigned value to semaglutide and liraglutide commercial ramps

Rating: Moderate Buy. Base fair value HKD 12.00 (~32% upside from HKD 9.08). Adding 2-year dividends brings total return to ~42%. The discount to peers, the cash fortress, and the conviction signal are sufficiently compelling for an initial position. A full Buy is withheld pending: (a) visibility that FY2026 earnings are not declining further below consensus; (b) first semaglutide commercial revenues; (c) clarity on VBP impact. The bear case (HKD 6.50) is real but requires significant deterioration across all business lines.

Key Risks

• FY2026 earnings decline: Consensus expects EPS to fall ~22% YoY from RMB 1.1065 (FY25A) to RMB 0.865 (FY26E), partly due to the non-recurring Novo Nordisk upfront recognised in FY2025. Further disappointment if VBP pricing cuts accelerate.
• Volume-based procurement (VBP): China's centralised drug purchasing continues to compress generic margins industry-wide. TUL's bulk medicine and finished-products segments are exposed.
• Revenue growth reversal: Consensus FY2026 revenue is RMB 12.9B vs FY2025's RMB 13.2B — a decline, suggesting core business headwinds outpace new product ramp.
• Pipeline execution risk: UBT251 milestones (up to US$1.8B) require successful clinical trials and regulatory approvals by Novo Nordisk. Clinical failure could eliminate the optionality premium.
• FX risk: Revenue and profits reported in RMB; stock priced in HKD. CNY depreciation would reduce HKD-equivalent returns.
• China regulatory / geopolitical: Drug approval timelines, inspection standards, and US-China trade tensions affect exports and licensing deals.
• Liquidity: ~HKD 17.9B market cap is mid-cap for HK; institutional coverage may be thin, amplifying volatility.
• Purchase price unknown: Average price paid on 8 July was not disclosed in the DI form; estimated at HKD 9.1–9.3. This creates mild uncertainty about the Chairman's exact entry level.

Sources

• HKEX Disclosure of Interests Form 3A — DA20260710E00719 (filed 10 Jul 2026; event 8 Jul 2026): HKEX DI System
• The United Laboratories International Holdings Ltd. — 2025 Annual Results Press Release (24 Mar 2026): irasia.com
• United Laboratories (3933.HK) — Financial Summary & Balance Sheet: Investing.com
• United Laboratories (3933.HK) — Stock Price & Overview: Investing.com UK
• United Laboratories (3933.HK) — Company Profile: AlphaSpread
• CSPC Pharmaceutical (1093.HK) — PE Ratio, Market Cap: companiesmarketcap.com
• Sino Biopharmaceutical (1177.HK) — PE Ratio: tradingeconomics.com
• Company HK$200M Share Buyback Announcement (Jun 2026): Minichart